What is NDC 73150-150?

73150-150 is the product NDC for Briumvi (ublituximab), Ublituximab 150 mg/6mL injection, solution, concentrate, listed with the FDA by TG Therapeutics, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

TG Therapeutics, Inc., NDC labeler code 73150. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Briumvi?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Briumvi NDC 73150-150 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)73150-150Labeler and product segments. Claims need a package NDC.

Product NDC at billing width73150-0150Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
73150-150-06	73150015006	1 VIAL, SINGLE-DOSE in 1 CARTON (73150-150-06) / 6 mL in 1 VIAL, SINGLE-DOSEMarketed from Dec 28, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Briumvi
Generic name (nonproprietary): ublituximab
Active ingredients: Ublituximab — 150 mg/6mL
Dosage form: Injection, Solution, Concentrate
Route: Intravenous
Labeler: TG Therapeutics, Inc.NDC labeler code 73150
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761238
Marketing start: Dec 28, 2022
Listing expires: Dec 31, 2027
Other FDA classes: CD20-directed Antibody Interactions (Mechanism)
Identifiers: Product ID 73150-150_4b34fc66-ea84-161b-e063-6294a90ac575SPL ID 4b34fc66-ea84-161b-e063-6294a90ac575SPL set ID 3a77cd8c-811b-407c-9140-d0c5c26435c2RxCUI 2626353, 2626359UNII U59UGK3IPCUPC 0373150150063
Pharmacologic class: CD20-directed Cytolytic Antibody

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N473150015006 followed by a unit qualifier and the quantity

Package 73150-0150-06. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 19, 2026.

Indications (excerpt from the label)

BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. BRIUMVI is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 , 14 ).

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 73150-150

What is NDC 73150-150?: 73150-150 is the product NDC for Briumvi (ublituximab), Ublituximab 150 mg/6mL injection, solution, concentrate, listed with the FDA by TG Therapeutics, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Briumvi (Ublituximab).
What is the active ingredient?: Ublituximab.
Who is the labeler?: TG Therapeutics, Inc., NDC labeler code 73150. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Briumvi?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Briumvi (Ublituximab) NDC 73150-150